['hiv-1 infection']
['darunavir/cobicistat', 'etravirine']

        Inclusion Criteria:

          1. Age ≥18 years old

          2. Documented HIV infection (western blot)

          3. Stable antiretroviral treatment including darunavir/cobicistat 800/150mg QD (cohort
             DRV) or etravirine 400mg QD (cohort ETR) for at least 4 weeks. Plasma HIV-1 RNA load
             <50 copies/mL for at least 12 weeks

          4. In women of childbearing age*, commitment to use at least one of these birth control
             methods: male or female condom with or without spermicide, cap, diaphragm or sponge
             with or without spermicide, intrauterine device, bilateral tubal occlusion,
             vasectomised partner, sexual abstinence during the study.

          5. Signed Informed Consent

               -  According to recommendations of Clinical Trial Facilitation Group (CTFG), a woman
                  is considered of childbearing potential: fertile, following menarche and until
                  becoming post-menopausal unless permanently sterile. Permanent sterilisation
                  methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy.

        Exclusion Criteria:

          1. Inadequate adherence to antiretroviral treatment (<90% during the last week)

          2. Patients who are taking or have been taking any other medication within the last two
             weeks prior to be recruited in the study, including herbal medicines and food
             supplements, with known interactions with darunavir, cobicistat or etravirine (i.e St.
             John's wort, grapefruit juice, some antibiotics such as erythromycin or rifampicin;
             antiepileptics such as phenytoin, phenobarbital or carbamazepine; antifungals such as
             itraconazole or ketoconazole; antiretrovirals such as ritonavir, efavirenz or
             nevirapine, among others.)

          3. Acute illness that could interfere with darunavir, cobicistat or etravirine
             pharmacokinetics (acute hepatitis…) within the prior 4 weeks

          4. Active AIDS-defining illness within the prior 4 weeks

          5. In women, pregnancy or breastfeeding.

          6. Evidence or clinical suspicion that the patient will not be able to complete the study
             treatment and protocol
      